Ehsan Anam N, Wu Catherine A, Minasian Alexandra, Bass Michelle, Sana Hamaiyal, Patel Aastha, Pace Lydia, Mekary Rania A, Ranganathan Kavitha
From the Program in Global Surgery and Social Change, Harvard Medical School, Boston, Mass.
Brigham and Women's Hospital, Boston, Mass.
Plast Reconstr Surg Glob Open. 2024 May 23;12(5):e5683. doi: 10.1097/GOX.0000000000005683. eCollection 2024 May.
Out-of-pocket costs are burdensome for breast cancer patients. Cost-reducing interventions, though implemented, have unclear comparative efficacy. This study aimed to critically evaluate characteristics of successful versus unsuccessful interventions designed to decrease out-of-pocket costs for breast cancer patients.
A systematic review was conducted in accordance with the PRISMA checklist. Embase, PubMed, Global Index Medicus, and Global Health were queried from inception to February 2021. Articles describing a financial intervention targeting costs for breast cancer screening, diagnosis, or treatment and addressing clinical or patient-level financial outcomes were included. Methodological quality was evaluated using the QualSyst tool. Interventions were organized in accordance with timing of implementation, with narrative description of intervention type, success, and outcomes.
Of the 11,086 articles retrieved, 21 were included in this review. Of these, 14 consisted of interventions during screening, and seven during diagnosis or treatment. Free/subsidized screening mammography was the most common screening intervention; 91% of these programs documented successful outcomes. Patient navigation and gift voucher programs demonstrated mixed success. The most successful intervention implemented during diagnosis/treatment was reducing medication costs. Low-cost programs and direct patient financial assistance were also successful. Limitations included lack of standardization in outcome metrics across studies.
Financial interventions reducing prices through free screening mammography and decreasing medication costs were most successful. Less successful interventions were not contextually tailored, including gift card incentivization and low-cost treatment modalities. These findings can facilitate implementation of broader, more generalizable programs to reduce costs and improve outcomes during evaluation and management of breast cancer.
自付费用对乳腺癌患者来说负担沉重。尽管实施了成本降低干预措施,但其相对疗效尚不清楚。本研究旨在严格评估旨在降低乳腺癌患者自付费用的成功与不成功干预措施的特点。
根据PRISMA清单进行系统评价。检索了Embase、PubMed、全球医学索引和全球卫生数据库,检索时间从建库至2021年2月。纳入描述针对乳腺癌筛查、诊断或治疗费用的财务干预措施并涉及临床或患者层面财务结果的文章。使用QualSyst工具评估方法学质量。根据实施时间对干预措施进行组织,并对干预类型、成功情况和结果进行叙述性描述。
在检索到的11,086篇文章中,本评价纳入了21篇。其中,14篇为筛查期间的干预措施,7篇为诊断或治疗期间的干预措施。免费/补贴乳腺钼靶筛查是最常见的筛查干预措施;这些项目中有91%记录了成功的结果。患者导航和礼品券项目的成功情况不一。诊断/治疗期间实施的最成功的干预措施是降低药物成本。低成本项目和直接患者财务援助也取得了成功。局限性包括各研究结果指标缺乏标准化。
通过免费乳腺钼靶筛查降低价格和降低药物成本的财务干预措施最为成功。不太成功的干预措施没有根据具体情况进行调整,包括礼品卡激励和低成本治疗方式。这些发现有助于实施更广泛、更具普遍性的项目,以在乳腺癌评估和管理期间降低成本并改善结果。